NYSE:CTLT Catalent - CTLT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $64.27 +1.63 (+2.60%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$61.04▼$64.4250-Day Range$47.96▼$74.2652-Week Range$40.69▼$115.33Volume1.38 million shsAverage Volume1.78 million shsMarket Capitalization$11.57 billionP/E Ratio28.44Dividend YieldN/APrice Target$96.30 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalent MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside49.8% Upside$96.30 Price TargetShort InterestHealthy3.04% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.64Based on 8 Articles This WeekInsider TradingSelling Shares$31,738 Sold Last QuarterProj. Earnings Growth9.12%From $2.85 to $3.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.71 out of 5 starsMedical Sector71st out of 1,005 stocksPharmaceutical Preparations Industry24th out of 486 stocks 3.3 Analyst's Opinion Consensus RatingCatalent has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $96.30, Catalent has a forecasted upside of 49.8% from its current price of $64.27.Amount of Analyst CoverageCatalent has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.04% of the outstanding shares of Catalent have been sold short.Short Interest Ratio / Days to CoverCatalent has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Catalent has recently increased by 4.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCatalent does not currently pay a dividend.Dividend GrowthCatalent does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalent has received a 72.90% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services", "Clinical research services", and "Pharmacovigilance services" products. See details.Environmental SustainabilityThe Environmental Impact score for Catalent is -0.85. Previous Next 2.0 News and Social Media Coverage News SentimentCatalent has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Catalent this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for CTLT on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Catalent to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,738.00 in company stock.Percentage Held by InsidersOnly 0.58% of the stock of Catalent is held by insiders.Percentage Held by Institutions99.38% of the stock of Catalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Catalent are expected to grow by 9.12% in the coming year, from $2.85 to $3.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalent is 28.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalent is 28.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 107.78.Price to Earnings Growth RatioCatalent has a PEG Ratio of 2.94. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCatalent has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalent (NYSE:CTLT) StockCatalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory managRead More Receive CTLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter. Email Address CTLT Stock News HeadlinesMarch 24, 2023 | finance.yahoo.comShould You Exit Catalent (CTLT)?March 21, 2023 | americanbankingnews.comBrokerages Set Catalent, Inc. (NYSE:CTLT) PT at $96.30March 26, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 20, 2023 | finance.yahoo.comCatalent (CTLT) Inks Deal for New & Effective Drug DeliveryMarch 19, 2023 | benzinga.comBronstein, Gewirtz & Grossman, LLC Notifies Catalent, Inc. (CTLT) Investors of Class Action and to Actively ParticipateMarch 19, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalent, Inc. - CTLTMarch 19, 2023 | americanbankingnews.comCatalent (NYSE:CTLT) Research Coverage Started at StockNews.comMarch 14, 2023 | benzinga.comCatalent Shareholder NoticeMarch 26, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 14, 2023 | benzinga.comCatalent, Inc. (CTLT) Class Action Alert: Contact Robbins LLP Regarding Representation as Lead Plaintiff in Class Action Against Catalent, Inc.March 11, 2023 | benzinga.comCatalent Shareholder Action ReminderMarch 11, 2023 | benzinga.comCTLT LAWSUIT ALERT: Levi & Korsinsky Notifies Catalent, Inc. Investors Of a Class Action Lawsuit and Upcoming DeadlineMarch 9, 2023 | finance.yahoo.comCatalent, Inc. to Present at March Investor ConferencesMarch 6, 2023 | finance.yahoo.comCatalent Appoints Sridhar Krishnan to Lead New Global Operational Excellence Strategy, "The Catalent Way"March 6, 2023 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Catalent, Inc. (CTLT)March 4, 2023 | businesswire.comNOTICE: Investors in Catalent, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CTLTMarch 3, 2023 | businesswire.comDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Catalent, Inc. (CTLT)February 28, 2023 | finance.yahoo.comCatalent Publishes Fourth Annual Corporate Responsibility Report Highlighting Achievements While Providing New Record Number of Patient TreatmentsFebruary 27, 2023 | businesswire.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Catalent, Inc. with Losses of $100,000 to Contact the FirmFebruary 25, 2023 | benzinga.comLabaton Sucharow LLP Announces Securities Class Action Lawsuit Filed Against Catalent, Inc. and Certain ExecutivesFebruary 25, 2023 | businesswire.comShareholder Alert: Robbins LLP Informs Investors of Class Action Against Catalent, Inc. (CTLT)February 24, 2023 | businesswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Catalent, Inc. with Losses of $100,000 to Contact the FirmFebruary 17, 2023 | finance.yahoo.comWill Catalent (CTLT) be Able to Provide Long-Term Returns?February 8, 2023 | finance.yahoo.comCatalent, Inc. (NYSE:CTLT) Q2 2023 Earnings Call TranscriptFebruary 8, 2023 | finance.yahoo.comCatalent Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsFebruary 7, 2023 | finance.yahoo.comCompared to Estimates, Catalent (CTLT) Q2 Earnings: A Look at Key MetricsFebruary 7, 2023 | finance.yahoo.comCatalent (CTLT) Misses Q2 Earnings EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CTLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter. Email Address CTLT Company Calendar Last Earnings2/07/2023Today3/25/2023Next Earnings (Estimated)5/02/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:CTLT CUSIPN/A CIK1596783 Webwww.catalent.com Phone(732) 537-6200Fax732-537-6480Employees19,000Year FoundedN/APrice Target and Rating Average Stock Price Forecast$96.30 High Stock Price Forecast$145.00 Low Stock Price Forecast$78.00 Forecasted Upside/Downside+49.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.26 Trailing P/E Ratio28.44 Forward P/E Ratio22.55 P/E Growth2.94Net Income$503 million Net Margins8.62% Pretax Margin10.60% Return on Equity11.40% Return on Assets5.14% Debt Debt-to-Equity Ratio0.86 Current Ratio1.91 Quick Ratio1.38 Sales & Book Value Annual Sales$4.83 billion Price / Sales2.40 Cash Flow$5.79 per share Price / Cash Flow11.10 Book Value$26.76 per share Price / Book2.40Miscellaneous Outstanding Shares180,090,000Free Float179,045,000Market Cap$11.57 billion OptionableOptionable Beta1.18 Key ExecutivesAlessandro MaselliPresident, Chief Executive Officer & DirectorThomas P. CastellanoChief Financial Officer & Senior Vice PresidentKay SchmidtSenior Vice President-Technical OperationsLim Chin WeiManager-Global Scientific AffairsJulien MeissonnierChief Scientific Officer & Vice PresidentKey CompetitorsSarepta TherapeuticsNASDAQ:SRPTViatrisNASDAQ:VTRSUnited TherapeuticsNASDAQ:UTHRTeva Pharmaceutical IndustriesNYSE:TEVADr. Reddy's LaboratoriesNYSE:RDYView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 403 shares on 3/23/2023Ownership: 0.027%North Star Asset Management Inc.Bought 10,357 shares on 3/6/2023Ownership: 0.038%Rockefeller Capital Management L.P.Sold 81,418 shares on 3/6/2023Ownership: 0.015%Voya Investment Management LLCBought 68,040 shares on 2/28/2023Ownership: 0.163%NatixisBought 7,000 shares on 2/24/2023Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions CTLT Stock - Frequently Asked Questions Should I buy or sell Catalent stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTLT shares. View CTLT analyst ratings or view top-rated stocks. What is Catalent's stock price forecast for 2023? 9 brokerages have issued 1-year target prices for Catalent's stock. Their CTLT share price forecasts range from $78.00 to $145.00. On average, they predict the company's share price to reach $96.30 in the next year. This suggests a possible upside of 49.8% from the stock's current price. View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts. How have CTLT shares performed in 2023? Catalent's stock was trading at $45.01 at the beginning of 2023. Since then, CTLT shares have increased by 42.8% and is now trading at $64.27. View the best growth stocks for 2023 here. Are investors shorting Catalent? Catalent saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 5,240,000 shares, a decline of 20.7% from the January 31st total of 6,610,000 shares. Based on an average trading volume of 2,930,000 shares, the days-to-cover ratio is presently 1.8 days. View Catalent's Short Interest. When is Catalent's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our CTLT earnings forecast. How were Catalent's earnings last quarter? Catalent, Inc. (NYSE:CTLT) released its quarterly earnings data on Tuesday, February, 7th. The company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.64 by $0.02. The company earned $1.15 billion during the quarter, compared to the consensus estimate of $1.12 billion. Catalent had a trailing twelve-month return on equity of 11.40% and a net margin of 8.62%. What ETFs hold Catalent's stock? ETFs with the largest weight of Catalent (NYSE:CTLT) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Alger 35 ETF (ATFV), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), SPDR S&P Pharmaceuticals ETF (XPH), VanEck Pharmaceutical ETF (PPH), Invesco Dynamic Biotechnology & Genome ETF (PBE), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Harbor Health Care ETF (MEDI). What guidance has Catalent issued on next quarter's earnings? Catalent updated its FY 2023 earnings guidance on Tuesday, February, 7th. The company provided EPS guidance of $3.13-$3.54 for the period, compared to the consensus earnings per share estimate of $3.20. The company issued revenue guidance of $4.63 billion-$4.88 billion, compared to the consensus revenue estimate of $4.69 billion. What is John R. Chiminski's approval rating as Catalent's CEO? 391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees. What other stocks do shareholders of Catalent own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO). What is Catalent's stock symbol? Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT." Who are Catalent's major shareholders? Catalent's stock is owned by a number of institutional and retail investors. Top institutional investors include T. Rowe Price Investment Management Inc. (9.21%), Veritas Asset Management LLP (6.21%), Artisan Partners Limited Partnership (4.35%), American Century Companies Inc. (2.30%), Geode Capital Management LLC (2.01%) and Franklin Resources Inc. (1.84%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph. View institutional ownership trends. How do I buy shares of Catalent? Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalent's stock price today? One share of CTLT stock can currently be purchased for approximately $64.27. How much money does Catalent make? Catalent (NYSE:CTLT) has a market capitalization of $11.57 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.26 on an earnings per share basis. How many employees does Catalent have? The company employs 19,000 workers across the globe. How can I contact Catalent? Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480. This page (NYSE:CTLT) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.